Holger Lembrér brings extensive experience as CFO and finance executive from international and publicly listed companies, primarily within the MedTech, Pharma and industrial sectors. He most recently served as CFO at Boule Diagnostics, where he held overall responsibility for the Group's finance function.

Prior to that, Holger was CFO at Oncopeptides and held several senior positions within ASSA ABLOY, including CFO for the Senior Care business area and Investor Relations Officer at Group level. He began his career as an auditor at EY.

- Holger combines solid financial expertise with strong business acumen and an international outlook. His experience from growth journeys in listed companies makes him a valuable addition to Enzymatica's management team, which together with the incoming CEO will drive the company's international expansion, says Bengt Baron, Chairman of the Board of Enzymatica AB.

- I look forward to joining Enzymatica in an exciting phase. The company has significant commercial potential and a dedicated team. Together with the incoming CEO, I aim to help strengthen global commercialization and build sustainable, profitable growth, says Holger Lembrér, incoming CFO of Enzymatica.

About Enzymatica

Enzymatica AB is a Swedish life science company specialising in enzyme-based medical devices that address respiratory health needs. The company's flagship product, ColdZyme®, is available in multiple markets. For more information, visit https://www.enzymatica.com.